135
121

RAISBECK, LARA, RODRÍGUEZ & RUEDA
MIEMBROS DE LA FIRMA
BAKER & McKENZIE

CALLE 35 No. 7-25, PISO 4
TELÉFONO: (57-1) 332-2600
BOGOTÁ, D.C. COLOMBIA
WWW.BAKERINFO.COM
OFFICE.BOGOTA@BAKERNET.COM

Señores
SUPERINTENDENCIA DE INDUSTRIA Y COMER(
DIVISION DE NUEVAS CREACIONES
E. S. D.

Re: Expediente No. **01.027.558.**
Solicitud de Patente de Invención titulada:
"METABOLITOS AGONISTAS/ANTAGONISTAS DE ESTROGENO".
Solicitante: **PFIZER PRODUCTS INC.**

RESPUESTA AL AUTO NOTIFICADO POR ESTADO No. 043
DE FECHA 17 DE MAYO DE 2001, OFICIO No. 1490

CARLOS R. OLARTE, mayor de edad y vecino de Bogotá D.C., identificado tal como aparece al pie de mi firma en mi carácter de apoderado de la sociedad en referencia, me permito manifestar lo siguiente ante el auto emanado por ese Despacho, dentro del término legal:

1. En atención a la única observación del Examinador, adjunto el documento de cesión del derecho de patente otorgado por los inventores a Pfizer Products Inc., debidamente legalizado y traducido.

2. Finalmente, adjunto la Copia Certificada del Documento de Prioridad No. 60/267,198 presentado ante la Oficina de Marcas y Patentes estadounidense el día 07 de abril de 2000. Así mismo, presento copia de la traducción al español del Capítulo Reivindicatorio del Documento de Prioridad.

Atentamente,

CARLOS R. OLARTE
C.C. No. 79.782.747 de Bogotá
T.P. 74.295

Anexos: Documento de Cesión.
Copia Certificada del Documento de Prioridad.
Traducción del Capítulo Reivindicatorio del Documento de Prioridad

X35 /123

TRADUCCION OFICIAL No. 135/01 de un documento escrito en inglés, el cual para su identificación se sella con el sello del Traductor. Esta es una Traducción Oficial efectuada el día 9 de abril de 2001 por la Sra. María Teresa Lara R., c.c. 41.568.055 de Bogotá, Traductora Oficial según Resolución No. 01016 del 2 de octubre de 1998, expedida por el Ministerio de Justicia.

= =

Traspaso del invento "Metabolitos Agonistas/Antagonistas del Estrógeno" a PFIZER PRODUCTS INC. Certificación notarial suscrita por Kenneth Greenwood, Notario Público de Egham, Surrey, Inglaterra, y legalizaciones subsiguientes.

MARIA TERESA LARA R.
TRADUCTORA OFICIAL
RESOLUCION No. 01016
DE MINJUSTICIA

PC10810ATMC
CO-1

TRASPASO

Por contraprestación valiosa pagada a nosotros por **PFIZER PRODUCTS INC.**, sociedad constituida conforme a las leyes del Estado de Connecticut, Estados Unidos de América, cuya dirección postal completa es Eastern Point Road, Groton, Connecticut 06340, Estados Unidos de América, por el presente vendemos y traspasamos a la citada **PFIZER PRODUCTS INC.**, todo nuestro derecho, título e interés en y sobre nuestro invento de una nueva y útil Mejora en **METABOLITOS AGONISTAS/ANTAGONISTAS DEL ESTRÓGEN** , en cuanto hace a la República de Colombia, tal como se indica y describe plenamente en la especificación, y por el presente autorizamos y solicitamos al Comisionado de Patentes de Colombia expedir dicha patente a nombre de la citada **PFIZER PRODUCTS INC.**, de conformidad con este traspaso.

En fe de lo cual, hemos firmado el presente.

(Fdo.) Wesley Warren Day	12 Marzo 2001
Lugar, fecha y firma - Wesley Warren DAY	Groton, Connecticut, EUA

134/124

(Fdo.) Kim Anne Johnson	07 Marzo 2001
Lugar, fecha y firma - Kim Anne JOHNSON	Groton, Connecticut, EUA
(Fdo.) Chandra Aggarwal Prakash	12 Marzo 2001
Lugar, fecha y firma - Chandra Aggarwal PRAKASH	Groton, Connecticut, EUA
(Fdo.) James Frederick Eggler	09 Marzo 2001
Lugar, fecha y firma - James Frederick EGGLER	Groton, Connecticut, EUA

[Sello] Certificado, verificado y autenticado
en la ciudad de Egham en Surrey

El día 19 de marzo de 2001

(Fdo.) Kenneth Greenwood

KENNETH GREENWOOD
NOTARIO PUBLICO
HORNE ENGALL AND FREEMAN

(Adherida, oblea dorada
con el sello notarial)

APOSTILLA

(Convención de La Haya del 5 de octubre de 1961)

1. País: Reino Unido de la Gran Bretaña e Irlanda del Norte

   Este documento público

2. ha sido firmado por K Greenwood

3. actuando en calidad de Notario Público

4. lleva el sello/estampilla de el antedicho Notario Público

135 125

Certificado

5. en Londres 6. el 19 de marzo de 2001

7. por el Secretario de Estado Principal de Su Majestad para Asuntos Exteriores y de la Commonwealth

8. No. **G874026**

9. Sello/Estampilla

(Sello de la Oficina de Asuntos Exteriores y de la Commonwealth)

10. Firma

(Fdo.) **J. Garbrah**

= =

MARIA TERESA LARA R.
TRADUCTORA OFICIAL
RESOLUCION No. 01016
DE MINJUSTICIA

La anterior es traducción fiel y completa del documento en referencia, de la cual se deja copia en este archivo para su confrontación.

María Teresa Lara R.
c.c. 41.568.055 de Bogotá
Traductora Oficial según
Resolución No. 01016 del
2 de octubre de 1998, del
Ministerio de Justicia

ASSIGNMENT

For valuable consideration paid to me (us) by **PFIZER PRODUCTS INC.** a corporation organized under the laws of the State of Connecticut, United States of America whose full post office address is Eastern Point Road, Groton, Connecticut 06340, United States of America, I (we) do hereby sell and assign to the said **PFIZER PRODUCTS INC.**, all my (our) right, title and interest in and to my (our) invention for a new and useful Improvement in **ESTROGEN AGONIST/ANTAGONIST METABOLITES** so far as the Republic of Colombia is concerned, as fully set forth and described in the specification, and I (we) do hereby authorize and request the Commissioner of Patents of Colombia to issue said patent to the said **PFIZER PRODUCTS INC.** in accordance with this assignment.

In witness whereof I (we) have hereunto set my (our) hand(s) this

Place, date and signature - Wesley Warren DAY	12 March 2001 Groton, Connecticut, USA
Place, date and signature - Kim Anne JOHNSON	07 March 2001 Groton, Connecticut, USA
Place, date and signature - Chandra Aggarwal PRAKASH	12 March 2001 Groton, Connecticut, USA
Place, date and signature - James Frederick EGGLER	09 March 2001 Groton, Connecticut, USA

Certified Verified and Authenticated
In The Town Of Egham In Surrey
This 16th Day of March 2001

KENNETH GREENWOOD
NOTARY PUBLIC
HORNE ENGALL AND FREEMAN

4584

127

APOSTILLE

(Hague Convention of 5 October 1961 / Convention de La Haye du 5 octobre 1961)

1. Country: United Kingdom of Great Britain and Northern Ireland
   Pays: Royaume-Uni de Grande-Bretagne et d'Irlande du Nord

   This public document / Le présent acte public

2. Has been signed by **K Greenwood**
   a été signé par

3. Acting in the capacity of **Notary Public**
   agissant en qualité de

4. Bears the seal/stamp of **The Said Notary Public**
   est revêtu du sceau/timbre de

Certified/Attesté

5. at London/à Londres

6. the/le **19 March 2001**

7. by Her Majesty's Principal Secretary of State for Foreign and Commonwealth Affairs /
   par le Secrétaire d'Etat Principal de Sa Majesté aux Affaires Etrangères et du Commonwealth.

8. Number/sous No **G874026**

9. Stamp:
   timbre:

10. Signature: **J. Garbrah**

For the Secretary of State / Pour le Secrétaire d'Etat


MARIA TERESA LIBA R.
TRADUCTORA OFICIAL
RESOLUCION No. 01016
DE MINJUSTICIA
1/35/01

LOS ESTADOS UNIDOS DE AMERICA

A TODOS AQUELLOS A QUIEN SE LES PRESENTE ESTE DOCUMENTO

DEPARTAMENTO DE COMERCIO DE LOS ESTADOS UNIDOS

Oficina de Patentes y Marcas de los Estados Unidos

06 Abril de 2001

ESTO ES PARA CERTIFICAR QUE LO ANEXADO AQUI ES UNA COPIA VERDADERA DE LOS REGISTROS DE LA OFICINA DE PATENTES Y MARCAS DE LOS ESTADOS UNIDOS DE AQUELLOS PAPELES DE ESTA SOLICITUD IDENTIFICADA ENSEGUIDA QUE CUMPLIÓ CON LOS REQUISITOS PARA SER OTORGADA UNA FECHA DE PRESENTACIÓN BAJO 35 USC 111.

NUMERO DE SOLICITUD: *60/267,198*

FECHA DE RADICACION: *07 de Abril de 2000*

Por autoridad de
El COMISIONADO DE PATENTES Y
MARCAS

Sello de la Oficina de Patentes y Marcas de los Estados Unidos de América

(Firmado Andrea T. Jones)
Andrea T. Jones
Oficial de
Certificación

Habiéndose descrito la invención como antecede, se declara como propiedad lo contenido en las siguientes

REIVINDICACIONES

1. Un metabolito de (-)-cis-6-fenil-5-[4-(2-pirrolidin-1-iletoxi)fenil]-5,6,7,8-tetrahidronaftalen-2-olcorrespondiente a la fórmula I:



(I)

en la que R_1 se selecciona de



$-NH(CH_2)_3COR_6$;

R_5 se selecciona de H ó CH_3;

R_2, R_3, R_4 y R_7 son iguales o diferentes y se seleccionan de H y OR_5; y

R_6 se selecciona de -OH ó $-NHCH_2COOH$, siempre que:

(a) si R_1 es  o $-NH(CH_2)_3COOH$ y

(b) R_2 es OH ó OCH_3 y R_3 y R_7 son H, ó si R_1 es como se definió en (a) anteriormente, y

(c) R_2 y R_7 son H y R_3 es OH ó OCH_3,

entonces R_4 no es H.

o un isómero óptico, estereoisómero, regioisómero o isómer configuracional o isómero geométrico de éste o un tautómer o sal, N-óxido, éster, sal de amonio cuaternario o profármaco farmacéuticamente aceptable de este.

2. Un metabolito de (-)-cis-6-fenil-5-[4-(2-pirrolidin-1-iletoxi)fenil]-5,6,7,8-tetrahidronaftalen-2-ol según la reivindicación 1, que se selecciona del grupo constituido por:



(III)



(IV)



(VII)



(VIII)

~~141~~

132



(IX)



(X)



(XIII)



(XV)



(XIX)



(XXV)

y los estereroisómeros, tautómeros, regioisómeros e isómeros configuracionales de éste, y las sales, N-óxidos, ésteres, sales de amonio cuaternario y profármacos de éste farmacéuticamente aceptables y las combinaciones de éstos.

3. Un estuche que comprende un metabolito de (-)-cis-6-fenil-5-[4-(2-pirrolidin-1-iletoxi)fenil]-5,6,7,8-tetrahidronaftalen-2-ol correspondiente a la fórmula I:



(I)

en la que R_1 se selecciona de



$-NH(CH_2)_3COR_6$;

R_5 se selecciona de H ó CH_3;

R_2, R_3, R_4 y R_7 son iguales o diferentes y se seleccionan de H y OR_5; y

R_6 se selecciona de -OH ó $-NHCH_2COOH$, siempre que:

(a) si R_1 es  o $-NH(CH_2)_3COOH$ y

(b) R_2 es OH ó OCH_3 y R_3 y R_7 son H, o si R_1 es como se definió en (a) anteriormente, y

(c) R_2 y R_7 son H y R_3 es OH ó OCH_3,

entonces R_4 no es H.

un isómero óptico, estereoisómero, regioisómero o isómero configuracional o isómero geométrico de éste o un tautómero sal, N-óxido, éster, sal de amonio cuaternario o profármac farmacéuticamente aceptable de este.

4. Un estuche según la reivindicación 3, en el que el citado metabolito de (-)-cis-6-fenil-5-[4-(2-pirrolidin-1-iletoxi)fenil]-5,6,7,8-tetrahidronaftalen-2-ol se selecciona del grupo constituido por:



(III)



(IV)



(VII)



(VIII)



(IX)



(X)



(XIII)



(XV)



(XIX)



(XXV)

y los estereroisómeros, tautómeros, regioisómeros e isómeros configuracionales de éste, y las sales, N-óxidos, ésteres, sales de amonio cuaternario y profármacos de éste farmacéuticamente aceptables y las combinaciones de éstos.

5. Un procedimiento de tratamiento de una enfermedad que comprende la administración a un sujeto necesitado de ello de una cantidad eficaz de un metabolito de (-)-cis-6-fenil-5-[4-(2-pirrolidin-1-iletoxi)fenil]-5,6,7,8-tetrahidronaftalen-2-ol correspondiente a la fórmula I:



(I)

en la que R_1 se selecciona de



$-NH(CH_2)_3COR_6$;

R_5 se selecciona de H ó CH_3;

R_2, R_3, R_4 y R_7 son iguales o diferentes y se seleccionan de H y OR_5; y

R_6 se selecciona de -OH ó $-NHCH_2COOH$, siempre que:

(a) si R_1 es  o $-NH(CH_2)_3COOH$ y

(b) R_2 es OH ó OCH_3 y R_3 y R_7 son H, o si R_1 es como se definió en (a) anteriormente, y

(c) R_2 y R_7 son H y R_3 es OH ó OCH_3,

entonces R_4 no es H.

o un isómero óptico, estereoisómero, regioisómero o isómero configuracional o isómero geométrico de éste o un tautómero o sal, N-óxido, éster, sal de amonio cuaternaria o profármaco farmacéuticamente aceptable de este.

6. Un procedimiento según la reivindicación 5, en el que el

citado metabolito de (-)-cis-6-fenil-5-[4-(2-pirrolidin-1-iletoxi)fenil]-5,6,7,8-tetrahidronaftalen-2-ol se selecciona del grupo constituido por:



(III)



(IV)



(VII)



(VIII)



(IX)



(X)



(XIII)



(XV)



(XIX)



(XXV)

y los estereroisómeros, tautómeros, regioisómeros e isómeros configuracionales de éste, y las sales, N-óxidos, ésteres, sales de amonio cuaternario y profármacos de éste farmacéuticamente aceptables y las combinaciones de éstos.

7. Un procedimiento según la reivindicación 5, reduciendo sustancialmente el citado procedimiento la propensión concomitante a efectos adversos asociados a la administración de estrógenos.

8. Un procedimiento según la reivindicación 6, reduciendo sustancialmente el citado procedimiento la propensión concomitante a efectos adversos asociados a la administración de estrógenos.

9. Una composición farmacéutica que comprende un metabolito de (-)-cis-6-fenil-5-[4-(2-pirrolidin-1-iletoxi)fenil]-5,6,7,8-tetrahidronaftalen-2-ol correspondiente a la fórmula I:



(I)

en la que R_1 se selecciona de



$-NH(CH_2)_3COR_6$;

R_5 se selecciona de H ó CH_3;

R_2, R_3, R_4 y R_7 son iguales o diferentes y se seleccionan de H y OR_5; y

R_6 se selecciona de -OH ó $-NHCH_2COOH$, siempre que:

(a) si R_1 es  o $-NH(CH_2)_3COOH$ y

(b) R_2 es OH ó OCH_3 y R_3 y R_7 son H, o si R_1 es como se definió en (a) anteriormente, y

(c) R_2 y R_7 son H y R_3 es OH ó OCH_3,

entonces R_4 no es H.

un isómero óptico, estereoisómero, regioisómero o isómero configuracional o isómero geométrico de éste o un tautómero o sal, N-óxido, éster, sal de amonio cuaternario o profármaco farmacéuticamente aceptable de este, y

un portador, vehículo o diluyente farmacéuticamente aceptable.

10. Una composición según la reivindicación 9, en la que el citado metabolito de (-)-cis-6-fenil-5-[4-(2-pirrolidin-1-iletoxi)fenil]-5,6,7,8-tetrahidronaftalen-2-ol se selecciona del grupo constituido por:

~~153~~

144



(III)



(IV)



(VII)



(VIII)



(IX)



(X)



(XIII)



(XV)



(XIX)



(XXV)

y los estereroisómeros, tautómeros, regioisómeros e isómeros configuracionales de éste, y las sales, N-óxidos, ésteres, sales de amonio cuaternario y profármacos de éste farmacéuticamente aceptables y las combinaciones de éstos.

11. Los compuestos:

6-fenil-5-[4-(2-pirrolidin-1-iletoxi)fenil]-5,6,7,8-tetrahidronaftalen-2,3-diol,

3-metoxi-7-fenil-8-[4-(2-pirrolidin-1-iletoxi)fenil]-5,6,7,8-tetrahidronaftalen-2-ol,

3-metoxi-6-fenil-5-[4-(2-pirrolidin-1-iletoxi)fenil]-5,6,7,8-tetrahidronaftalen-2-ol,

6-fenil-5-[4-(2-pirrolidin-1-iletoxi)fenil]-5,6,7,8-tetrahidronaftalen-1,2-diol,

2-metoxi-6-fenil-5-[4-(2-pirrolidin-1-iletoxi)fenil]-5,6,7,8-tetrahidronaftalen-1-ol,

1-metoxi-6-fenil-5-[4-(2-pirrolidin-1-iletoxi)fenil]-5,6,7,8-tetrahidronaftalen-2-ol,

y los estereroisómeros, tautómeros, regioisómeros e

isómeros configuracionales de éstos, y las sales, N-óxidos, ésteres, sales de amonio cuaternario y profármacos de éstos farmacéuticamente aceptables y las combinaciones de éstos.

157

148

PA 393462

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

April 06, 2001

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: ***60/267,198***
FILING DATE: ***April 07, 2000***

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS

Andrea T Jones

ANDREA T JONES
Certifying Officer

jc491 U.S. PTO
04/07/00

PROVISIONAL APPLICATION COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION under 37 CFR 1.53 (b)(2).

	Docket Number	PC10810	Type a plus sign (+) inside this box	+

INVENTOR(s)/APPLICANT(s)

LAST NAME	FIRST NAME	MIDDLE INITIAL	RESIDENCE (CITY AND EITHER STATE OR FOREIGN COUNTRY)
DAY	WESLEY	W.	OLD LYME, CT
JOHNSON	KIM	A.	EAST HAVEN, CT
PRAKASH	CHANDRA	A.	GALES FERRY, CT

TITLE OF THE INVENTION *(280 characters max)*

ESTROGEN AGONIST/ANTAGONIST METABOLITES

CORRESPONDENCE ADDRESS

Gregg C. Benson
Pfizer Inc
Patent Department, MS 4519
Eastern Point Road, Groton, CT 06340

ENCLOSED APPLICATION PARTS *(check all that apply)*

☒ Specification Number of Pages 26 ☒ Claim(s) Number of Pages 25

☒ Drawing(s) Number of Sheets 18 ☒ Other (specify) Abstract page 1

METHOD OF PAYMENT *(check one)*

☐ ☒	A check or money order is enclosed to cover the Provisional filing fees. The Commissioner is hereby authorized to charge all required filing fees to, and credit any overpayment to Deposit Account Number: 16-1445. Two copies of this page are enclosed.	PROVISIONAL FILING FEE AMOUNT($)	$150.00

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No.

☐ Yes, the name of the U.S. Government agency and the Government contract number are:

Respectfully submitted,

SIGNATURE Steven W. Collier DATE: 4-7-2000

TYPED or PRINTED NAME Steven W. Collier REGISTRATION NO 42,429 *(if appropriate)*

☐ Additional inventors are being named on separately numbered sheets attached hereto.

PROVISIONAL APPLICATION FILING ONLY

Express Mail No.

EXPRESS MAIL NO. EK506127595US

PC10810SWC

ESTROGEN AGONIST / ANTAGONIST METABOLITES

FIELD OF THE INVENTION

This invention relates to compounds that are mammalian metabolites of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol. The compounds of the invention are useful as standards in analytical assays.

BACKGROUND OF THE INVENTION

Pharmacologically, (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol (PPTN) is an estrogen agonist / antagonist that is disclosed in U.S. Patent No. 5,552,412. An "estrogen agonist / antagonist" is compound that affects some of the same receptors that estrogen does, but not necessarily all, and in some instances, it antagonizes or blocks estrogen. It is also known as a "selective estrogen receptor modulator" (SERM). Estrogen agonists / antagonists may also be referred to as antiestrogens although they have some estrogenic activity at some estrogen receptors. Estrogen agonists / antagonists are therefore not what are commonly referred to as "pure antiestrogens". Antiestrogens that can also act as agonists are referred to as Type I antiestrogens. Type I antiestrogens activate the estrogen receptor to bind tightly in the nucleus for a prolonged time but with impaired receptor replenishment (Clark, et al., Steroids 1973;22:707; Capony, et al., Mol Cell Endocrinol, 1975;3:233).

The compounds of the present invention are metabolites of PPTN and are believed to possess significant pharmacological activities similar to those possessed by the parent compound; PPTN.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a representative HPLC radiochromatogram for urinary metabolites of PPTN in mice following oral administration. The scale of the

vertical axis is radioactivity in counts per minute (CPM). The scale of the horizontal axis is retention time in minutes.

Figure 2 is a representative HPLC radiochromatogram for fecal metabolites of PPTN in mice following oral administration. The scale of the vertical axis is radioactivity in counts per minute (CPM). The scale of the horizontal axis is retention time in minutes.

Figure 3 is a representative HPLC radiochromatogram for circulating metabolites of PPTN in mice following oral administration. The scale of the vertical axis is radioactivity in counts per minute (CPM). The scale of the horizontal axis is retention time in minutes.

Figure 4 is the fragmentation pattern and mass spectral data for PPTN metabolite XI. The scale of the vertical axis is relative abundance. The scale of the horizontal axis is the mass to charge ratio; m/z.

Figure 5 is the fragmentation pattern and mass spectral data for PPTN metabolite XII. The scale of the vertical axis is relative abundance. The scale of the horizontal axis is the mass to charge ratio; m/z.

Figure 6 is the fragmentation pattern and mass spectral data for PPTN metabolite XXI. The scale of the vertical axis is relative abundance. The scale of the horizontal axis is the mass to charge ratio; m/z.

Figure 7 is the fragmentation pattern and mass spectral data for PPTN metabolite XIV. The scale of the vertical axis is relative abundance. The scale of the horizontal axis is the mass to charge ratio; m/z.

Figure 8 is the fragmentation pattern and mass spectral data for PPTN metabolite VI. The scale of the vertical axis is relative abundance. The scale of the horizontal axis is the mass to charge ratio; m/z.

Figure 9 is the fragmentation pattern and mass spectral data for PPTN metabolite II. The scale of the vertical axis is relative abundance. The scale of the horizontal axis is the mass to charge ratio; m/z.

Figure 10 is the fragmentation pattern and mass spectral data for PPTN metabolite XVI. The scale of the vertical axis is relative abundance. The scale of the horizontal axis is the mass to charge ratio; m/z.

Figure 11 is the fragmentation pattern and mass spectral data for PPTN metabolite X. The scale of the vertical axis is relative abundance. The scale of the horizontal axis is the mass to charge ratio; m/z.

Figure 12 is the fragmentation pattern and mass spectral data for PPTN metabolite XVII. The scale of the vertical axis is relative abundance. The scale of the horizontal axis is the mass to charge ratio; m/z.

Figure 13 is the fragmentation pattern and mass spectral data for PPTN metabolite IV. The scale of the vertical axis is relative abundance. The scale of the horizontal axis is the mass to charge ratio; m/z.

Figure 14 is the fragmentation pattern and mass spectral data for PPTN metabolite XV. The scale of the vertical axis is relative abundance. The scale of the horizontal axis is the mass to charge ratio; m/z.

Figure 15 is the fragmentation pattern and mass spectral data for PPTN metabolite V. The scale of the vertical axis is relative abundance. The scale of the horizontal axis is the mass to charge ratio; m/z.

Figure 16 is the fragmentation pattern and mass spectral data for PPTN metabolite XIII. The scale of the vertical axis is relative abundance. The scale of the horizontal axis is the mass to charge ratio; m/z.

Figure 17 is the fragmentation pattern and mass spectral data for PPTN metabolite IX. The scale of the vertical axis is relative abundance. The scale of the horizontal axis is the mass to charge ratio; m/z.

~~162~~

153

Figure 18 is the fragmentation pattern and mass spectral data for PPTN metabolite VIII. The scale of the vertical axis is relative abundance. The scale of the horizontal axis is the mass to charge ratio; m/z.

SUMMARY OF THE INVENTION

This invention relates to compounds that are mammalian metabolites of the estrogen agonist / antagonist; PPTN.

A second aspect of the invention relates to pharmaceutical compositions comprising a metabolite of PPTN or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt thereof and a pharmaceutically acceptable carrier, vehicle or diluent.

A third aspect of the invention relates to methods of treating disease comprising administering an effective amount of a metabolite of PPTN possessing pharmacological activity or a pharmaceutically acceptable salt, N-oxide, ester, or quaternary ammonium salt thereof. The metabolites of PPTN are effective while substantially reducing the concomitant liability of adverse effects associated with estrogen administration.

As a fourth aspect, the present invention provides for kits for use by a consumer to treat disease. The kit comprises a) a mammalian metabolite of PPTN; and, optionally, b) instructions describing a method of using the metabolite of PPTN to treat disease. The instructions may also indicate that the kit is for treatment of disease while substantially reducing the concomitant liability of adverse effects associated with estrogen administration.

A fifth aspect of the invention relates to kits for use as analytical standards in measuring metabolites of PPTN or pharmaceutically acceptable salts, N-oxides, esters, and quaternary ammonium salts thereof. The kits comprise a substantially pure form of a PPTN metabolite and a container for holding the metabolite.

As a sixth aspect, the present invention provides for the use of mammalian metabolites of PPTN or pharmaceutically acceptable salts, N-oxides, esters, and quaternary ammonium salts thereof for the manufacture of a medicament.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to metabolites of PPTN. The metabolites correspond to compounds represented by Formula I:



(I)

wherein R_1 is selected from  ,  ,  or

$-NH(CH_2)_3COR_6$;

R_6 is selected from H, CH_3, glucuronic acid and SO_3H;

R_2, R_3, R_4 and R_7 are the same or different and are selected from H and OR_5; and

R_5 is selected from -OH, $-NHCH_2COOH$, glucuronic acid and $-NHCH_2CH_2SO_3H$,

provided that:

(a) if R_1 is  , or $-NH(CH_2)_3COOH$ and

(b) R_2 is OH or OCH_3 and R_3 and R_7 are H, or if R_1 is as defined in (a) above and

(c) R_2 and R_7 are H and R_3 is OH or OCH_3,

then R_4 is not H.

169

155

Preferred metabolite compounds of PPTN include those exemplified in Table I.

Table I: Preferred Metabolites of PPTN:

	(II)
	(III)
	(IV)
	(V)
	(VI)

156

	(VII)
	(VIII)
	(IX)
	(X)
	(XI)
	(XII)

	(XIII)
	(XIV)
	(XV)
	(XVI)
	(XVII)
	(XVIII)

167

158

	(XIX)
	(XX)
	(XXI)
	(XXII)
	(XXIII)

	(XXIV)
	(XXV)

In another aspect, this invention relates to substantially pure metabolites of PPTN as described above.

Unless otherwise stated the following definitions apply:

"Treatment" as used herein includes preventative (e.g., prophylactic) and palliative treatment and "treating" as used herein refers to the act of providing preventative and/or palliative treatment.

A "subject" is an animal including the human species that is treatable with the compounds, compositions, methods and kits of the present invention. The term "subject" or "subjects" is intended to refer to both the male and female gender unless one gender is specifically indicated.

"Adverse effects associated with estrogen" include breast tenderness, breast cancer, bloating, headache, increased blood clotting and menstrual bleeding in women. Unopposed estrogen therapy increases the risk of endometrial carcinoma. Women on long-term estrogen therapy may have an increased risk that is not reversed by concurrent progestin (N. Engl. J. Med.

1995;332:1589). In men, the adverse effects of estrogen include increased blood clotting, gynecomastia, feminization and decreased libido.

The term "post-menopausal women" is defined to include not only women of advanced age who have passed through menopause, but also women who have been hysterectomized or for some other reason have suppressed estrogen production, such as those who have undergone long-term administration of corticosteroids, suffer from Cushions' syndrome or have gonadal dysgenesis.

"Breast cancer" is defined as a malignant proliferation of epithelial cells lining the ducts or lobules of the breast.

"Glucuronic acid" is the substituent that is transferred to a metabolite or transferred to a parent compound to form a metabolite from the phase II conjugation reaction of glucuronidation. Glucuronic acid reacts with an acid or alcohol or phenol moiety on the metabolite or parent compound to form the "glucuronide" The glucoronide substituent is abbreviated in the formulae herein as "Glu" or "Glucuronide".

"Sulfuric acid" is the substituent that is transferred to a metabolite or transferred to a parent compound to form a metabolite from the phase II conjugation reaction of sulfation. Sulfuric acid reacts with an alcohol or phenol moiety on the metabolite or parent compound to form the "sulfate".

"Co-administration" of a combination of a PPTN metabolite and an additional compound or additional compounds means that these components can be administered together as a composition or as part of the same, unitary dosage form. "Co-administration" also includes administering a PPTN metabolite and an additional compound or additional compounds separately but as part of the same therapeutic treatment program or regimen. The components need not necessarily be administered at essentially the same time, although they can if so desired. Thus "co-administration" includes, for example, administering a PPTN metabolite and an additional compound as separate dosages or dosage forms, but at the same time. "Co-administration" also includes separate administration at different times and in any order. For example, where appropriate a patient may take one or

more component(s) of the treatment in the morning and the one or more of the other component(s) at night.

The chemist of ordinary skill will recognize that certain compounds of this invention will contain one or more atoms which may be in a particular stereochemical, tautomeric, or geometric configuration, giving rise to stereoisomers, tautomers, regio and configurational isomers. All such isomers and mixtures thereof are included in this invention. Hydrates and solvates of the compounds of this invention are also included.

The subject invention also includes isotopically-labeled compounds, which are identical to those shown in Formulae I-XXV, among other compounds encompassed by the invention, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine and chlorine, such as ^{2}H, ^{3}H, ^{13}C, ^{14}C, ^{15}N, ^{18}O, ^{17}O, ^{31}P, ^{32}P, ^{35}S, ^{18}F and ^{36}Cl, respectively. Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds or of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopically-labeled compounds of the present invention, for example those into which radioactive isotopes such as ^{3}H and ^{14}C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., ^{3}H, and carbon-14, i.e., ^{14}C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., ^{2}H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased *in vivo* half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labeled compounds of formulae I-XXV of this invention and prodrugs thereof can generally be prepared by carrying out the procedures exemplified below or those known in the art. ^{14}C-PPTN can be prepared by the methods outlined and exemplified in U.S. Patent No. 5,552,412 by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.

The metabolites of PPTN, in their substantially pure form or in mixtures of known composition, may be used as analytical standards for in vitro or in vivo metabolism studies or as intermediates for the chemical synthesis or biosynthesis of new chemical entities. The metabolites may be isolated as solids or in solutions.

The compounds of the present invention are believed to be useful for the treatment of disease. Examples of diseases for which the compounds may be effective include osteoporosis, breast cancer, hyperlipidemia, atherosclerosis, Alzheimer's disease, cataracts, loss of libido, male sexual dysfunction, colon cancer, skin wrinkles, autoimmune disease, alopecia, acne, cardiovascular disease, cataracts, diabetes, endometriosis, female sexual dysfunction, hyperglycemia, obesity, obsessive compulsive disorder, premenstrual syndrome, prostatic carcinoma, prostatic hyperplasia, pulmonary hypertension, reperfusion damage, rheumatoid arthritis, seborrhea, senile gynecomastia, testosterone deficiency and conditions responsive to testosterone elevation, Turner's syndrome, uterine fibroids, and the promotion of wound healing. Methods for treating one or more of the above diseases or conditions comprise the administration of an effective amount of a PPTN metabolite.

When used for the treatment of one or more of the above conditions, PPTN metabolites may be used (either co-administered separately or within the same pharmaceutical composition) in combination with PPTN and statins, such as simvastatin, disclosed in U.S. 4,444,784; pravastatin, disclosed in U.S. 4,346,227; cerivastatin, disclosed in U.S. 5,502,199; mevastatin, disclosed in U.S. 3,983,140; velostatin, disclosed in U.S. 4,448,784 and U.S. 4,450,171; fluvastatin, disclosed in U.S. 4,739,073; compactin, disclosed in U.S. 4,804,770; lovastatin, disclosed in U.S. 4,231,938; dalvastatin, disclosed in European Patent Application Publication No. 738510 A2; fluindostatin, disclosed in European Patent Application Publication No. 363934 A1; atorvastatin, disclosed in U.S. Patent No. 4,681,893; atorvastatin calcium, disclosed in U.S. Patent No. 5,273,995; dihydrocompactin, disclosed in U.S. 4,450,171; ZD-4522, disclosed in U.S. Patent No. 5,260,440; bervastatin, disclosed in U.S. Patent No. 5,082,859; and NK-104, disclosed in U.S. Patent No. 5,102,888. PPTN metabolites may also be used in combination

172

163

with bisphosphonate compounds such as alendronic acid, alendronate, cimadronate, clodronic acid, clodronate, 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonic acid, etidronic acid, ibandronate, neridronate, olpadronate, pamidronate, piridronate, risedronate, tiludronate and zolendronate. Additionally, PPTN metabolites may be used in combination with cyclic guanosine 3',5' monophosphate elevators such as sildenafil (1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxy-phenyl]sufonyl]-4-methylpiperazine citrate salt).

The pharmaceutically acceptable acid addition salts of the compounds of this invention may be formed of the compound itself, or of any of its esters, and include the pharmaceutically acceptable salts which are often used in pharmaceutical chemistry. For example, salts may be formed with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfonic acids including such agents as naphthalenesulfonic, methanesulfonic and toluenesulfonic acids, sulfuric acid, nitric acid, phosphoric acid, tartaric acid, pyrosulfuric acid, metaphosphoric acid, succinic acid, formic acid, phthalic acid, lactic acid and the like, most preferable with hydrochloric acid, citric acid, benzoic acid, maleic acid, acetic acid and propionic acid.

The compounds of this invention, as discussed above, can be administered in the form of pharmaceutically acceptable salts. The salts are conveniently formed, as is usual in organic chemistry, by reacting a compound of this invention with a suitable acid, such as have been described above. The salts are quickly formed in high yields at moderate temperatures, and often are prepared by merely isolating the compound from a suitable acidic wash as the final step of the synthesis. The salt-forming acid is dissolved in an appropriate organic solvent, or aqueous organic solvent, such as an alkanol, ketone or ester. On the other hand, if a compound of this invention is desired in the free base form, it is isolated from a basic final wash step, according to the usual practice. A preferred technique for preparing hydrochlorides is to dissolve the free base in a suitable solvent and dry the solution thoroughly, as over molecular sieves, before bubbling hydrogen chloride gas through it.

When used as a medicament, the dose of a compound of this invention to be administered to a human is rather widely variable and subject to the judgement of the attending physician. It should be noted that it may be necessary to adjust the dose of a compound when it is administered in the form of a salt, such as a laureate, the salt forming moiety of which has an appreciable molecular weight. The general range of effective administration rates of the compounds is from about 0.001 mg/day to about 200 mg/day. A preferred range is from about 0.01 mg/day to 100 mg/day. Of course, it is often practical to administer the daily dose of compound in portions, at various hours of the day. However, in any given case, the amount of compound administered will depend on such factors as the solubility of the active component, the formulation used and the route of administration.

The route of administration of the compounds of this invention is not critical. The compounds may be absorbed from the alimentary tract, however, the compounds may be administered percutaneously, or as suppositories for absorption by the rectum, if desired in a given instance. All of the usual types of compositions may be used, including tablets, chewable tablets, capsules, solutions, parenteral solutions, troches, suppositories and suspensions. Compositions are formulated to contain a daily dose, or a convenient fraction of daily dose, in a dosage unit, which may be a single tablet or capsule or convenient volume of a liquid.

In general, all of the compositions are prepared according to methods usual in pharmaceutical chemistry and/or isolated from in vivo or in vitro metabolism reactions such as those exemplified herein. The parent compound, PPTN, is prepared by those procedures outlined and/or exemplified in U.S. patent 5,552,412. The metabolites may be synthesized directly or may be formed by in vitro or in vivo enzymatic or metabolic reactions such as those described in the Examples.

Methods of formulation are well known in the art and are disclosed, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 19th Edition (1995). Pharmaceutical compositions for use within the present invention can be in the form of sterile, non-pyrogenic liquid solutions or

PA

165

suspensions, coated capsules, suppositories, lyophilized powders, transdermal patches or other forms known in the art.

Capsules are prepared by mixing the compound with a suitable diluent and filling the proper amount of the mixture in capsules. The usual diluents include inert powdered substances such as starch of many different kinds, powdered cellulose, especially crystalline and microcrystalline cellulose, sugars such as fructose, mannitol and sucrose, grain flours and similar edible powders.

Tablets are prepared by direct compression, by wet granulation, or by dry granulation. Their formulations usually incorporate diluents, binders, lubricants and disintegrators as well as the compound. Typical diluents include, for example, various types of starch, lactose, mannitol, kaolin, calcium phosphate or sulfate, inorganic salts such as sodium chloride and powdered sugar. Powdered cellulose derivatives are also useful. Typical tablet binders are substances such as starch, gelatin and sugars such as lactose, fructose, glucose and the like. Natural and synthetic gums are also convenient, including acacia, alginates, methylcellulose, polyvinylpyrrolidine and the like. Polyethylene glycol, ethylcellulose and waxes can also serve as binders.

A lubricant may be necessary in a tablet formulation to prevent the tablet and punches from sticking in the die. The lubricant is chosen from such slippery solids as talc, magnesium and calcium stearate, stearic acid and hydrogenated vegetable oils.

Tablet disintegrators are substances which facilitate the disintegration of a tablet to release a compound when the tablet becomes wet. They include starches, clays, celluloses, algins and gums, more particularly, corn and potato starches, methylcellulose, agar, bentonite, wood cellulose, powdered natural sponge, cation-exchange resins, alginic acid, guar gum, citrus pulp and carboxymethylcellulose, for example, may be used as well as sodium lauryl sulfate.

Tablets are often coated with sugar as a flavor and sealant, or with film-forming protecting agents to modify the dissolution properties of the tablet. The

AF

166

compounds may also be formulated as chewable tablets, by using large amounts of pleasant-tasting substances such as mannitol in the formulation, as is now well-established in the art.

When it is desired to administer a compound as a suppository, the typical bases may be used. Cocoa butter is a traditional suppository base, which may be modified by addition of waxes to raise its melting point slightly. Water-miscible suppository bases comprising, particularly, polyethylene glycols of various molecular weights are in wide use.

The effect of the compounds may be delayed or prolonged by proper formulation. For example, a slowly soluble pellet of the compound may be prepared and incorporated in a tablet or capsule. The technique may be improved by making pellets of several different dissolution rates and filling capsules with a mixture of the pellets. Tablets or capsules may be coated with a film which resists dissolution for a predictable period of time. Even the parenteral preparations may be made long-acting, by dissolving or suspending the compound in oily or emulsified vehicles which allow it to disperse only slowly in the serum.

The term "prodrug" means compounds that are transformed in vivo to yield a compound of the present invention. The transformation may occur by various mechanisms, such as through hydrolysis in blood. A good discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.

For example, if a compound of the present invention contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as (C_1-C_8)alkyl, (C_2-C_{12})alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1-

176

167

(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-(alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N-(C_1-C_2)alkylamino(C_2-C_3)alkyl (such as β-dimethylaminoethyl), carbamoyl-(C_1-C_2)alkyl, N,N-di(C_1-C_2)alkylcarbamoyl-(C_1-C_2)alkyl and piperidino-, pyrrolidino- or morpholino(C_2-C_3)alkyl.

Similarly, if a compound of the present invention comprises an alcohol functional group, a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as (C_1-C_8)alkanoyloxymethyl, 1-((C_1-C_8)alkanoyloxy)ethyl, 1-methyl-1-((C_1-C_8)alkanoyloxy)ethyl, (C_1-C_8)alkoxycarbonyloxymethyl, N-(C_1-C_8)alkoxycarbonylaminomethyl, succinoyl, (C_1-C_8)alkanoyl, α-amino(C_1-C_4)alkanoyl, arylacyl and α-aminoacyl, or α-aminoacyl-α-aminoacyl, where each α-aminoacyl group is independently selected from the naturally occurring L-amino acids, $P(O)(OH)_2$, $-P(O)(O(C_1-C_8)alkyl)_2$ or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate).

If a compound of the present invention comprises an amine functional group, a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as R^X-carbonyl, R^XO-carbonyl, $NR^XR^{X'}$-carbonyl where R^X and $R^{X'}$ are each independently ((C_1-C_{10})alkyl, (C_3-C_7)cycloalkyl, benzyl, or R^X-carbonyl is a natural α-aminoacyl or natural α-aminoacyl-natural α-aminoacyl, $-C(OH)C(O)OY^X$ wherein (Y^X is H, (C_1-C_6)alkyl or benzyl), $-C(OY^{X0})Y^{X1}$ wherein Y^{X0} is (C_1-C_4) alkyl and Y^{X1} is ((C_1-C_6)alkyl, carboxy(C_1-C_6)alkyl, amino(C_1-C_4)alkyl or mono-N- or di-N,N-(C_1-C_6)alkylaminoalkyl, $-C(Y^{X2})Y^{X3}$ wherein Y^{X2} is H or methyl and Y^{X3} is mono-N- or di-N,N-(C_1-C_6)alkylamino, morpholino, piperidin-1-yl or pyrrolidin-1-yl.

As used herein, the term "effective amount" means an amount of compound of the methods of the present invention that is capable of treating the specific diseases and pathological conditions. The specific dose of a compound administered according to this invention will, of course, be determined by the

177

168

particular circumstances surrounding the case including, for example, the compound administered, the route of administration, the state of being of the subject, and the severity of the pathological condition being treated.

Advantageously, the present invention also provides kits for use by a consumer for treating disease. The kits comprise a) a pharmaceutical composition comprising an estrogen agonist / antagonist and a pharmaceutically acceptable carrier, vehicle or diluent; and, optionally, b) instructions describing a method of using the pharmaceutical composition for treating the specific disease. The instructions may also indicate that the kit is for treating disease while substantially reducing the concomitant liability of adverse effects associated with estrogen administration.

A "kit" as used in the instant application includes a container for containing the separate unit dosage forms such as a divided bottle or a divided foil packet. The container can be in any conventional shape or form as known in the art which is made of a pharmaceutically acceptable material, for example a paper or cardboard box, a glass or plastic bottle or jar, a re-sealable bag (for example, to hold a "refill" of tablets for placement into a different container), or a blister pack with individual doses for pressing out of the pack according to a therapeutic schedule. The container employed can depend on the exact dosage form involved, for example a conventional cardboard box would not generally be used to hold a liquid suspension. It is feasible that more than one container can be used together in a single package to market a single dosage form. For example, tablets may be contained in a bottle which is in turn contained within a box.

An example of such a kit is a so-called blister pack. Blister packs are well known in the packaging industry and are being widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a preferably transparent plastic material. During the packaging process, recesses are formed in the plastic foil. The recesses have the size and shape of individual tablets or capsules to be packed or may have the size and shape to accommodate multiple tablets and/or capsules to be packed. Next, the tablets or capsules are placed in the recesses accordingly and the sheet of relatively stiff

material is sealed against the plastic foil at the face of the foil which is opposite from the direction in which the recesses were formed. As a result, the tablets or capsules are individually sealed or collectively sealed, as desired, in the recesses between the plastic foil and the sheet. Preferably the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure on the recesses whereby an opening is formed in the sheet at the place of the recess. The tablet or capsule can then be removed via said opening.

It maybe desirable to provide a written memory aid, where the written memory aid is of the type containing information and/or instructions for the physician, pharmacist or subject, e.g., in the form of numbers next to the tablets or capsules whereby the numbers correspond with the days of the regimen which the tablets or capsules so specified should be ingested or a card which contains the same type of information. Another example of such a memory aid is a calendar printed on the card e.g., as follows "First Week, Monday, Tuesday," . . . etc . . . . "Second Week, Monday, Tuesday, . . ." etc. Other variations of memory aids will be readily apparent. A "daily dose" can be a single tablet or capsule or several tablets or capsules to be taken on a given day.

Another specific embodiment of a kit is a dispenser designed to dispense the daily doses one at a time. Preferably, the dispenser is equipped with a memory-aid, so as to further facilitate compliance with the regimen. An example of such a memory-aid is a mechanical counter which indicates the number of daily doses that has been dispensed. Another example of such a memory-aid is a battery-powered micro-chip memory coupled with a liquid crystal readout, or audible reminder signal which, for example, reads out the date that the last daily dose has been taken and/or reminds one when the next dose is to be taken.

Based on a reading of the present description and claims, certain modifications to the compositions and methods described herein will be apparent to one of ordinary skill in the art. The claims appended hereto are intended to encompass these modifications.

All references and patents cited herein are incorporated by reference.

~~129~~ 170

EXAMPLES

Example 1: Estrogen Receptor Binding.

Estrogen and PPTN metabolite binding affinity is measured by the following protocol:

cDNA cloning of human ERα: The coding region of human ERα is cloned by RT-PCR from human breast cancer cell mRNA using Expand™ High Fidelity PCR System according to manufacturer's instructions (Boehringer-Mannheim, Indianapolis, IN). PCR products are cloned into pCR2.1 TA Cloning Kit (Invitrogen, Carlsbad, CA) and sequenced. Each receptor coding region is subcloned into the mammalian expression vector pcDNA3 ((Invitrogen, Carlsbad, CA).

Mammalian cell expression. Receptor proteins are overexpressed in 293T cells. These cells, derived from HEK293 cells (ATCC, Manassas, VA), have been engineered to stably express large T antigen and can therefore replicate plasmids containing a SV40 origin of replication to high copy numbers. 293T cells are transfected with either hERα-pcDNA3 or hERβ-pcDNA3 using lipofectamine as described by the manufacturer (Gibco/BRL, Bethesda, MD). Cells are harvested in phosphate buffered saline (PBS) with 0.5 mM EDTA at 48 h post-transfection. Cell pellets are washed once with PBS/EDTA. Whole cell lysates are prepared by homogenization in TEG buffer (50 mM Tris pH 7.4, 1.5 mM EDTA, 50 mM NaCl, 10% glycerol, 5 mM DTT, 5 µg/ml aprotinin, 10 µg/ml leupeptin, 0.1 mg/ml Pefabloc™ (Pentapharm AG, Basel, Switzerland) using a dounce homogenizer. Extracts are centrifuged at 100,000 x g for 2 h at 4°C and supernatants are collected. Total protein concentrations are determined using BioRad reagent (BioRad, Hercules, CA).

Competition binding assay. The ability of PPTN metabolites to inhibit [^{3}H]-estradiol binding is measured by a competition binding assay using dextran-coated charcoal as has been described (Leake RE, Habib F 1987 Steroid

180

171

hormone receptors: assay and characterization. In: B. Green and R.E. Leake (eds). Steroid Hormones a Practical Approach. IRL Press Ltd, Oxford. 67-92.) 293T cell extracts expressing either hERα or hERβ are incubated in the presence of increasing concentrations of PPTN metabolite and a fixed concentration of [^{3}H]-estradiol (141 Ci/mmol, New England Nuclear, Boston, MA) in 50 mM TrisHCl pH 7.4, 1.5 mM EDTA, 50 mM NaCl, 10% glycerol, 5 mM DTT, 0.5 mg/mL β-lactoglobulin in a final volume of 0.2 mL. All PPTN metabolites are dissolved in dimethylsulfoxide or aqueous solvent. The final concentration of receptor is 50 pM with 0.5 nM [^{3}H]-estradiol. After 16 h at 4°C, dextran-coated charcoal (20 µL) is added. After 15 min at room temperature the charcoal is removed by centrifugation and the radioactive ligand present in the supernatant is measured by scintillation counting. All reagents are obtained from Sigma (St. Louis, MO) unless otherwise indicated.

Example 2: Inhibition of In Vitro Human Breast Tumor Cell Growth.

The *in vitro* antiproliferative effects of PPTN metabolites are tested using two types of human breast cancer cell lines: first, MCF-7 cells, which contain ER as well as progesterone receptors (PgR), and second, MDA-MB-231 cells, which lack ER and PgR, and enable the determination of an effect that is independent of the ER mechanism. The effect of PPTN metabolites on the growth of these different cell lines is determined by incubation of the cells with various estrogen agonist / antagonist concentrations for 6 days. The antiproliferative effects are then determined by direct cell counts.

Example 3: Biosynthesis of PPTN Metabolites in Mice.

A dose of ^{14}C-PPTN is prepared as a suspension in 0.5% methylcellulose (W/W) at a concentration of about 0.898 mg/g. The dosing solution is assayed in duplicate before and after dosing. Metabolites of PPTN are determined by high performance liquid chromatography (HPLC) with radioactivity detection and identified by liquid chromatography with mass spectrometry / mass spectrometry analysis (LC/MS/MS).

For this Example, a group of CD-1 mice (N=9/gender, 25-30 g) is dosed by oral gavage and housed separately in groups of three animals per cage (3/sex) in Nalgene™ metabolism cages (Nalge Nunc International, Rochester, NY) for the separate collection of urine and feces. The gavage tube is weighed before and after dosing to determine the actual dose given to each animal. Urine, feces and cage washes are quantitatively collected into preweighed sample containers for seven days from each cage at 0-24, 24-48, 48-72, 72-96, 96-120, 120-144 and 144-168 hours post dose. The weights of urine, feces and cage rinse obtained at different time points are recorded. The urine and fecal samples are divided and stored at -20° C in the dark until analysis. A second group of animals (N=6/gender, 25-30 g) is dosed by oral gavage for the identification of circulating metabolites. In this second group, 3 animals of each gender are sacrificed at 1 and 4 hours post dose and blood is collected in heparinized tubes.

Urine (approximately 3 ml from the 0-48 hour pool) from each group is centrifuged and the supernatant is transferred to a clean tube and concentrated under nitrogen with an evaporator. The residue is dissolved in approximately 1 ml of HPLC mobile phase and an aliquot (80-100 μl) is injected onto the HPLC without further purification. The fecal homogenates (~2 g) from the animals at 0-72 hours post dose are pooled on the basis of weights collected at each time interval and the pooled samples are diluted with acetonitrile (6 ml). The suspension is stirred overnight on a magnetic stirrer and centrifuged. The supernatant is removed, and the extraction is repeated with methanol (6 ml) and methanol:water (50:50, 6 ml). All the supernatants are combined and small aliquots are counted. The organic solvent is evaporated using the Turbo Vap. The residue is dissolved in approximately 1 ml of methanol:ammonium acetate (1:1). An aliquot (20-50 µl) is injected onto the HPLC. Pooled plasma (2 ml, 1 and 4 hour) is diluted with 4 ml of acetonitrile and the precipitated protein are removed by centrifugation. The pellet is washed with an additional 2 ml of acetonitrile and both the supernatants are combined. The supernatants are concentrated on an evaporator, and the residues are reconstituted in 500 µl of methanol:ammonium acetate (1:1). An aliquot (100 µl) is injected on the HPLC.

HPLC is carried out with a Hewlett Packard HP1100 quaternary pump and autosampler (Hewlett Packard, Palo Alto, California) equipped with a radioactivity

182

173

detector (β-RAM, IN/US Systems, Inc., Tampa, FL). Chromatography is carried out on a Beckman Ultrasphere™ C-18 column (4.6 mm x 250 mm, 5 µm) (Beckman Coulter, Inc., Fullerton, CA) with a binary mixture of 10 mM ammonium acetate (solvent A) and methanol (solvent B). The mobile phase initially consists of solvent A/solvent B (80:20), it is then linearly programmed to solvent A/solvent B (20:80) over 30 min and then programmed to solvent A/solvent B (5:95) in 5 minutes and held for 5 min. The mobile phase composition is returned to the starting solvent mixture over 5 min. The system is allowed to equilibrate for approximately 15 min before making the next injection. A flow rate of 1.0 ml/min is used for all analyses.

Quantification of the metabolites is carried out by measuring the radioactivity in the individual peaks that are separated by HPLC using the radioactivity detector. The radioactivity detector provides an integrated printout in counts per minute (CPM) and the percentage of the radiolabelled material, as well as the peak representation. The radioactivity detector is operated in the homogeneous liquid scintillation counting mode with the addition of 3 ml/min of mobile phase-compatible scintillation cocktail to the effluent post-uv detection.

Identification of the metabolites is performed on a Finnigan TSQ 7000 LC/MS/MS (Thermo Quest, San Jose, CA). The effluent from the HPLC column is split and about 50 µl/min is introduced into the mass spectrometer atmospheric ionization source via a pneumatically assisted electrospray interface. The remaining effluent is directed into the flow cell of the radioactivity detector. The radioactivity detector response is recorded in real time by the mass spectrometer data system which provides simultaneous detection of radioactivity and mass spectrometry data. The delay in response between the two detectors is about 0.2 min with the mass spectrometric response recorded earlier. The electrospray interface is operated at about 4000 V and the mass spectrometer is operated in the positive mode. Collision induced dissociation (CID) studies are performed using argon gas at a collision energy of about 30 to about 40 eV and a collision gas pressure of about 2.3 mTorr.

Example 4: Biosynthesis of PPTN Metabolites in Humans.

^{14}C-PPTN (tartrate salt) is prepared with a specific activity of about 1.93 mCi/mMol.

Normal healthy male subjects between the ages of 18 and 45 years are chosen to participate in the study. Subjects enter the clinical facility approximately 12 hours before dosing, and remain there for at least 576 hours after dosing under continuous medical observation. All subjects fast for at least 12 hours before being given a single dose of approximately 20 mg free base equivalents of ^{14}C-PPTN (~80 µCi/subject). The dose is administered in an open fashion in the morning. A standard meal is provided 4 hours later. The dosing formulation is prepared by suspending the radiolabeled PPTN in water. Subjects are required to refrain from lying down, eating or drinking caffeinated and carbonated beverages during the first four hours after drug administration.

After dosing, blood sufficient to yield 20 ml of plasma was collected at 24 and 48 hours for the purposes of metabolite identification. All samples are labeled and immediately frozen.

Plasma samples (20 ml) from each subject at 24 and 48 hours post dose are mixed with 40 ml of acetonitrile, vortexed and sonicated. The mixtures are centrifuged and the supernatants removed. The pellets are mixed with 5 ml of acetonitrile, centrifuged, and the two supernatants are combined. The supernatants are concentrated to dryness under nitrogen. The residues are reconstituted in 300 µl of methanol/water (1:1), centrifuged to remove insoluble matters, and 100 µl aliquots are injected into the HPLC column. PPTN metabolites extracted from the plasma samples are identified by HPLC with radioactivity detection and by LC/MS/MS as described in Example 3 above.

Example 5: Isolation and Identification of Mouse PPTN Metabolites.

A biosynthesis of PPTN metabolites was carried out in mouse by the methods described in Example 3. Mice were dosed at a dose of 20 mg/kg. Urine

and feces were collected from a group of mice. A second group of mice were dosed and blood collected for the isolation and identification of circulating metabolites. The results of the study are presented in figures 1-18. Figures 1-3 are representative radiochromatograms of urinary, fecal and circulating metabolites, respectively. Representative mass spectral data together with structural assignments for the metabolites isolated by HPLC are given in figures 4-18.

Claims:

1. A metabolite of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol corresponding to formula I:



(I)

wherein R_1 is selected from  ,  ,  or

$NH(CH_2)_3COR_6$;

R_5 is selected from H, CH_3, glucuronic acid and SO_3H;

R_2, R_3, R_4 and R_7 are the same or different and are selected from H and OR_5; and

R_6 is selected from -OH, $-NHCH_2COOH$, glucuronic acid and $-NHCH_2CH_2SO_3H$, provided that:

(a) if R_1 is  , or $-NH(CH_2)_3COOH$ and

(b) R_2 is OH or OCH_3 and R_3 and R_7 are H, or if R_1 is as defined in (a) above and

(c) R_2 and R_7 are H and R_3 is OH or OCH_3,

then R_4 is not H;

or an optical, stereo, regio or configurational isomer or geometric isomer thereof or a tautomer, pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or prodrug thereof.

2. A metabolite of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol according to claim 1 that is selected from the group consisting of :



(II)



(III)



(IV)



(V)



(VI)



(VII)



(VIII)



(IX)



(X)



(XI)



(XII)



(XIII)



(XIV)



(XV)



(XVI)

189

180



(XVII)



(XVIII)



(XIX)



(XX)



(XXI)



(XXII)



(XXIII)



(XXIV)



(XXV)

and stereoisomers, tautomers, regio and configurational isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof and combinations thereof.

191

182

3. A kit comprising a metabolite of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol corresponding to formula I:



(I)

wherein R_1 is selected from  ,  ,  or

$-NH(CH_2)_3COR_6$;

R_5 is selected from H, CH_3, glucuronic acid and SO_3H;

R_2, R_3, R_4 and R_7 are the same or different and are selected from H and OR_5; and

R_6 is selected from -OH, $-NHCH_2COOH$, glucuronic acid and $-NHCH_2CH_2SO_3H$,

provided that:

(a) If R_1 is  , or $-NH(CH_2)_3COOH$ and

(b) R_2 is OH or OCH_3 and R_3 and R_7 are H, or if R_1 is as defined in (a) above and

(c) R_2 and R_7 are H and R_3 is OH or OCH_3,

then R_4 is not H;

or an optical, stereo, regio or configurational isomer or geometric isomer thereof or a tautomer, pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or prodrug thereof.

4. A kit according to claim 3 wherein said metabolite of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol is selected from the group consisting of :

~~192~~ 183



(II)



(III)



(IV)



(V)



(VI)



(VII)



(VIII)



(IX)



(X)



(XI)



(XII)



(XIII)



(XIV)



(XV)



(XVI)



(XVII)

,



(XVIII)

,



(XIX)

,



(XX)

,



(XXI)

,



(XXII)



(XXIII)



(XXIV)



(XXV)

and stereoisomers, tautomers, regio and configurational isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters,.quaternary ammonium salts, and prodrugs thereof and combinations thereof.

197

188

5. A method of treating disease comprising administering to a subject in need thereof, an effective amount of a metabolite of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol corresponding to formula I:



(I)

wherein R_1 is selected from  or

$NH(CH_2)_3COR_5$;

R_5 is selected from H, CH_3, glucuronic acid and SO_3H;

R_2, R_3, R_4 and R_7 are the same or different and are selected from H and OR_5; and

R_5 is selected from -OH, $-NHCH_2COOH$, glucuronic acid and $-NHCH_2CH_2SO_3H$,

provided that:

(a) if R_1 is  , or $-NH(CH_2)_3COOH$ and

(b) R_2 is OH or OCH_3 and R_3 and R_7 are H, or if R_1 is as defined in (a) above and

(c) R_2 and R_7 are H and R_3 is OH or OCH_3,

then R_4 is not H;

or an optical, stereo, regio or configurational isomer or geometric isomer thereof or a tautomer, pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or prodrug thereof.

6. A method as claimed in claim 5 wherein said metabolite of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol is selected from the group consisting of :



(II)



(III)



(IV)



(V)



(VI)

199
190



(VII)



(VIII)



(IX)



(X)



(XI)



(XII)



(XIII)



(XIV)



(XV)



(XVI)



(XVII)



(XVIII)



(XIX)



(XX)



(XXI)



(XXII)



(XXIII)



(XXIV)



(XXV)

and stereoisomers, tautomers, regio and configurational isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof and combinations thereof.

7. A method as claimed in claim 5 wherein said method substantially reduces the concomitant liability of adverse effects associated with estrogen administration.

203

194

8. A method as claimed in claim 6 wherein said method substantially reduces the concomitant liability of adverse effects associated with estrogen administration.

9. A pharmaceutical composition comprising a metabolite of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol corresponding to formula I:



(I)

wherein R_1 is selected from  or

$-NH(CH_2)_3COR_6$;

R_6 is selected from H, CH_3, glucuronic acid and SO_3H;

R_2, R_3, R_4 and R_7 are the same or different and are selected from H and OR_6; and

R_5 is selected from -OH, $-NHCH_2COOH$, glucuronic acid and $-NHCH_2CH_2SO_3H$, provided that:

(a) if R_1 is  , or $-NH(CH_2)_3COOH$ and

(b) R_2 is OH or OCH_3 and R_3 and R_7 are H, or if R_1 is as defined in (a) above and

(c) R_2 and R_7 are H and R_5 is OH or OCH_3,

then R_4 is not H;

or an optical, stereo, regio or configurational isomer or geometric isomer thereof or a tautomer, pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or prodrug thereof, and

a pharmaceutically acceptable carrier, vehicle or diluent.

10. A composition according to claim 9 wherein said metabolite of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol is selected from the group consisting of :



(II)



(III)



(IV)



(V)



(VI)



(VII)



(VIII)



(IX)



(X)



(XI)



(XII)



(XIII)



(XIV)



(XV)



(XVI)



(XVII)



(XVIII)



(XIX)



(XX)



(XXI)



(XXII)



(XXIII)



(XXIV)



(XXV)

and stereoisomers, tautomers, regio and configurational isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof and combinations thereof.

210
201

ABSTRACT

This invention relates to compounds that are mammalian metabolites of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol. The compounds of the invention can be used as standards for analytical assays or as intermediates for the further chemical synthesis or biosynthesis of chemical entities. The invention also relates to pharmaceutical compositions for the treatment of disease and methods of treating disease.

Patent Application
Docket No.: PC10810SWC

2H 1

202

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION OF: Wesley W. Day et al.	:
APPLICATION NO.: Not Yet Known	: Examiner: Not Yet Known
FILING DATE: April 7, 2000 (requested)	: Group Art Unit: Not Yet Known
TITLE: Estrogen Agonist / Antagonist Metabolites	:

Commissioner for Patents
Washington, D.C. 20231

Sir:

DECLARATION OF JANICE DENISON

I, Janice Denison, declare as follows:

1. I have been employed by Pfizer Inc. in the Legal Division since October 4, 1999 and am presently an Executive Assistant.

2. On April 7, 2000, I prepared an express mailing envelope (Express Mail Post Office to Addressee service of the United States Postal Service) that contained the following documents:

Provisional application specification;
Provisional application cover sheet;
Assignment;
Assignment recordation cover sheet; and
Return-receipt postcard.

3. The specification of the provisional application was titled "Estrogen Agonist / Antagonist Metabolites" and had the docket number PC10810SWC.

4. I placed an express mailing label having the number EK506127595US upon the express mail envelope containing the above-identified papers.

5. I placed the express mailing label number on each document that was placed in the express mail envelope.

6. The express mailing label was addressed to "Assistant Commissioner of Patents and Trademarks, Box Assignment, Washington, D.C. 20231."

7. I took the express mail envelope with the express mailing label to our corporate mailroom where correct postage was determined and placed on the envelope.

8. At or about 4:20 p.m., I drove to the U.S. Post Office in Groton, CT.

9. At or about 4:57 p.m., I handed the express mail envelope containing the above-identified documents to a postal employee.

10. The postal employee checked the express mail envelope for correct postage and then wrote a "date-in" date of April 7, 2000 on the express mailing label.

11. The postal employee handed me a copy of the express mailing label with the "date-in" date written upon it.

12. The U.S. Post Office in Groton, CT closes at 5:00 p.m.

13. All statements made herein of my own knowledge are true and all statements made on information and belief are believed to be true; and further these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and any such willful false statements may jeopardize the validity of the above-referenced application or any patent issuing therefrom.

Date: August 22, 2000 Janice Denison

Janice Denison

~~213~~
209




6026571 98 . 0040700
1300
1200
1100
1000
900
800
700
600
500
400
300
200
100
5.0
10.0
15.0
20.0
25.0
30.0
35.0
IV
X
XV
V
XIII
PPTN
IX
VIII
VI

206

09257198.040700



~~216~~

207



208


462
239
224
130
-H_2O
112
Glucuronide-O
HO
O
N
COOH
100
90
80
70
60
50
40
30
20
10
0
130
112
239
276
87
144
224
265
334
353
426
462
64
169
213
188
319
365
422
626
636
100
150
200
250
300
350
400
450
500
550
600


460
269
192
98
Glucuronide-O
CH3O
N
175
OH

602671198 040700
100
98
269
460
237
175
71
107
137
171
182
224
241
284
328
133
145
206
336
379
436
482
501
546
638
100
150
200
250
300
350
400
450
500
550
600

~~214~~

210





~~220~~

211


430
98
239
O
HO3SO
N
HO


98
239
341
430
448
466
0
10
20
30
40
50
60
70
80
90
100
150
200
250
300
350
400
450
500


428
237
192
98
Glucuronide-O
O
O
N

6026719B .04070D0
100
90
80
70
60
50
40
30
20
10
0
98
237
209
71
95
116
181
192
279
308
319
347
371
428
447
470
487
100
150
200
250
300
350
400
450
500
550
600


444
253
192
98
Glucuronide-O
CH3O
O
N
175

x5
444
98
221
253
175
192
182
91
113
137
228
271
294
319
378
406
459
488
494
531
620
100
150
200
250
300
350
400
450
500
550
600









225

216


98
239
192
O
HO
N
145
HO

x5
98
145
239
192
107
71
133
430
68
96
121
157
180
195
237
250
280
297
312
325
370
384
424
100
150
200
250
300
350
400
450

226
217





218



228

219


98
237
HO
O
N
O

98
71
56
83
101
131
137
147
173
187
184
209
219
237
244
270
284
303
313
329
347
367
375
401
431
447
100
150
200
250
300
350
400
450


98
239
192
O
HO
HO
N
161


x5
100
80
70
60
50
40
30
20
10
0
98
71
91
69
84
123
147
161
171
192
204
221
239
251
282
288
313
344
382
388
428
430
100
150
200
250
300
350
400
450


253
192
98
HO
CH3O
N
175


RT: 33.45-33.71 AV: 9 SM: 7G NL: 3.70E4
SRM ms2 444.00
x5
98
253
444
221
175
143
192
162
91
112
71
239
100
150
200
250
300
350
400

Industria y Comercio
SUPERINTENDENCIA

222

2do. EXAMEN DE FORMA PATENTE DE INVENCION

Folio 232

Radicación no 01-27558

Concepto Técnico no 1833 Clasificación Internacional de Patentes: A 61K 31/085

Practicado el examen de acuerdo a lo establecido en el Art. 38 de la Decisión 486 se determinó que esta solicitud de Patente de Invención:

SI [✔] NO [ ]	Contiene un resumen de la invención (Art.26-e).
SI [✔] NO [ ]	Contiene el título o nombre de la invención (Art.27-d).
SI [✔] NO [ ]	Contiene la descripción de la invención (Art.26-b).
SI [✔] NO [ ]	NO ES APLICABLE [ ] Contiene los dibujos necesarios para comprender la invención (Art.26-d)
SI [✔] NO [ ]	Contiene una o más reivindicaciones. (Art.26-c).
SI [ ] NO [ ]	NO ES APLICABLE [✔] Han sido desarrollados los productos y/o procedimientos a partir de recursos genéticos o de sus productos derivados de los que cualquiera de los Países Miembros es país de origen. (Art. 26- h).
SI [ ] NO [ ]	NO ES APLICABLE [✔]Los productos y/o procedimientos han sido obtenidos o desarrollados a partir de los conocimientos tradicionales de las comunidades indígenas, afroamericanas, o locales de los países miembros, de acuerdo a lo establecido en la Decisión 391 y sus modificaciones y reglamentaciones vigentes.(Art.26-i).
SI [ ] NO [✔]	La invención se refiere a un producto relativo a un material biológico. (Art.26-J).
SI [✔] NO [ ]	La prioridad coincide con la materia reivindicada.
SI [✔] NO [ ]	CUMPLE LOS REQUISITOS TÉCNICOS

OBSERVACIONES Y OTROS: SI [ ] NO [✔] ver hoja(s) anexa(s)

EXAMINADOR TÉCNICO
202048

Bogotá D. C., 4 de Diciembre de 2002.

Carrera 13 No. 27-00 Piso 5 y 10
Conmutador: 334 12 21-2-3-4
Fax: 281 31 25 e-mail: info@sic.gov.co
Santa Fe de Bogotá D.C. - Colombia

Industria y Comercio
SUPERINTENDENCIA

223

Folio 235

2020
Bogotá DC

Doctor
CARLOS R OLARTE
Apoderado

REFERENCIA:	Radicación No.	01-27558
	Trámite	002
	Evento	001
	Actuación	416
	Oficio No.	2339
	Folios	001

Teniendo en cuenta que la solicitud de privilegio de patente que se tramita bajo el expediente indicado en la referencia, reúne los requisitos de forma establecidos en los artículos 26 y 27 de la Decisión 486 de la Comisión de la Comunidad Andina, y en las demás disposiciones vigentes sobre la materia, se envía el extracto de la solicitud a la Oficina de Comunicaciones para efecto de su publicación en la Gaceta de Propiedad Industrial, conforme lo establece el artículo 40 de la misma Decisión.

Cúmplase
Dado en Bogotá DC, a los

ALIX CARMENZA CESPEDES DE VERGEL
Jefe de la División de Nuevas Creaciones

202048